Elagolix
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometriosis
Conditions
Endometriosis
Trial Timeline
May 27, 2014 → May 23, 2017
NCT ID
NCT02143713About Elagolix
Elagolix is a phase 3 stage product being developed by AbbVie for Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02143713. Target conditions include Endometriosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05038878 | Approved | Terminated |
| NCT02143713 | Phase 3 | Completed |
| NCT01931670 | Phase 3 | Completed |
| NCT01760954 | Phase 3 | Completed |
| NCT01620528 | Phase 3 | Completed |
Competing Products
20 competing products in Endometriosis